A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder
The DOI matches its Crossref record; 50 of the 50 references it cites were found in a registry or an index.
Abstract
As many as half of obsessive-compulsive disorder (OCD) patients treated with an adequate trial of serotonin reuptake inhibitors (SRIs) fail to fully respond to treatment and continue to exhibit significant symptoms. Many studies have assessed the effectiveness of antipsychotic augmentation in SRI-refractory OCD. In this systematic review, we evaluate the efficacy of antipsychotic augmentation in treatment-refractory OCD. The electronic databases of PubMed, PsychINFO (1967-2005), Embase (1974-2000) and the Cochrane Central Register of Controlled Trials (CENTRAL, as of 2005, Issue 3) were searched for relevant double-blind trials using keywords 'antipsychotic agents' or 'neuroleptics' and 'obsessive-compulsive disorder'. Search results and analysis were limited to double-blind, randomized control trials involving the adult population. The proportion of subjects designated as treatment responders was defined by a greater than 35% reduction in Yale Brown Obsessive-Compulsive Scale (Y-BOCS) rating during the course of augmentation therapy. Nine studies involving 278 participants were included in the analysis. The meta-analysis of these studies demonstrated a significant absolute risk difference (ARD) in favor of antipsychotic augmentation of 0.22 (95% confidence interval (CI): 0.13, 0.31). The subgroup of OCD patients with comorbid tics have a particularly beneficial response to this intervention, ARD=0.43 (95% CI: 0.19, 0.68). There was also evidence suggesting OCD patients should be treated with at least 3 months of maximal-tolerated therapy of an SRI before initiating antipsychotic augmentation owing to the high rate of treatment response to continued SRI monotherapy (25.6%). Antipsychotic augmentation in SRI-refractory OCD is indicated in patients who have been treated for at least 3 months of maximal-tolerated therapy of an SRI. Unfortunately, only one-third of treatment-refractory OCD patients show a meaningful treatment response to antipsychotic augmentation. There is sufficient evidence in the published literature, demonstrating the efficacy of haloperidol and risperidone, and evidence regarding the efficacy of quetiapine and olanzapine is inconclusive. Patients with comorbid tics are likely to have a differential benefit to antipsychotic augmentation.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“there are some case reports that methylphenidate can worsen OCD symptoms [174] and for some patients antipsychotic medications that reduce dopamine levels are effective [175] (Table 3).”
From Toward a neurocircuit-based taxonomy to guide treatment of obsessive-compulsive disorder (2021) · cites this paper as [175]
In the citing paper
“A meta-analysis of the adult literature examining the use of antipsychotic augmentation in the treatment of OCD showed that the NNT for OCD and tics was 2.3 compared to 5.9 for those with OCD alone.”
From Practice Parameter for the Assessment and Treatment of Children and Adolescents With Tic Disorders (2013) · cites this paper as [139]
Citations
Cites
Bias in meta-analysis detected by a simple, graphical test
Egger, M., Smith, G. D., Schneider, M., & Minder, C. (1997) · BMJ · doi:10.1136/bmj.315.7109.629 · Cited by 56,722
Kessler, R. C. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950010008002 · Cited by 12,370
(1996) · Cited by 6,884
Charbonneau, D. H. (2005) · Europe PMC (PubMed Central) · Cited by 2,041
The Epidemiology of Obsessive-Compulsive Disorder in Five US Communities
Karno, M. (1988) · Archives of General Psychiatry · doi:10.1001/archpsyc.1988.01800360042006 · Cited by 1,351
A 40-Year Follow-up of Patients With Obsessive-compulsive Disorder
Skoog, G., & Skoog, I. (1999) · Archives of General Psychiatry · doi:10.1001/archpsyc.56.2.121 · Cited by 632
McDougle, C. J., Epperson, C. N., Pelton, G. H., Wasylink, S., & Price, L. H. (2000) · Archives of General Psychiatry · doi:10.1001/archpsyc.57.8.794 · Cited by 571
McDougle, C. J. (1994) · Archives of General Psychiatry · doi:10.1001/archpsyc.1994.03950040046006 · Cited by 570
The International Journal of Neuropsychopharmacology
Lerer, B., Frazer, A., Stahl, S., Farde, L., & Lesch, P. (1998) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145798009018 · Cited by 501
The Epidemiology and Differential Diagnosis of Obsessive-Compulsive Disorder
Rasmussen, S. A., & Eisen, J. L. (1992) · Zwangsstörungen / Obsessive-Compulsive Disorders · doi:10.1007/978-3-642-77608-3_1 · Cited by 493
Research works printed but not linked: 2
- Muller C . Vorlaufige Mitteilung zur langen Katamnese der Zwangskranken. Nervenartz 1953; 24: 112–115.
- Rennie TAC . Prognosis in the Psychoneurosis: Benign and Malignant Developments, Current Problems in Psychiatric Diagnosis. New York: Grune & Stratton Inc, 1953.
Cited by
Items 201–300 of 638
Bellia, F., Vismara, M. E. M., Annunzi, E., Cifani, C., Benatti, B., Dell’Osso, B. M., & D’Addario, C. (2020) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2020.10.040 · Cited by 35
How resistant is ‘treatment‐resistant’ obsessive‐compulsive disorder in youth?
Krebs, G., Isomura, K., Lang, K., Jassi, A. D., Heyman, I., Diamond, H., Advani, J., Turner, C. M., & Mataix‐Cols, D. (2014) · British Journal of Clinical Psychology · doi:10.1111/bjc.12061 · Cited by 33
“For youngpeoplewhodonot respond to trials of twodifferent SSRIs a course of clomipramine is recommended, and for thosewho remain non-responsive, evidence from trials in adults with OCD suggest that augmentation with a low dose anti-psychotic can be considered (Bloch et al., 2006).”
BackgroundReal-time fMRI Biofeedback Targeting the Orbitofrontal Cortex for Contamination Anxiety
Hampson, M., Stoica, T., Saksa, J. R., Scheinost, D., Qiu, M., Bhawnani, J., Pittenger, C., Papademetris, X., & Constable, R. T. (2012) · Journal of Visualized Experiments · doi:10.3791/3535 · Cited by 36
Brakoulias, V., & Stockings, E. (2018) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2018.1540590 · Cited by 38
Antipsychotic augmentation in the treatment of obsessive-compulsive disorder
Jaisoorya, T. S., & Thamby, A. (2019) · Indian Journal of Psychiatry · doi:10.4103/psychiatry.indianjpsychiatry_519_18 · Cited by 39
“There are six meta-analyses to date, all of which have included double-blind, randomized, placebo-controlled trials comparing augmentation of SSRIs with antipsychotics to placebo supplementation in treatment-resistant OCD.”
BackgroundInfluentialBallı, T., Metin, B., Tülay, E. E., Tan, O., Sayar, G. H., Taş, C., Arıkan, M. K., & Tarhan, N. (2020) · Clinical Neurophysiology · doi:10.1016/j.clinph.2019.11.063 · Cited by 32
Cassin, S. E., Richter, M. A., Zhang, K. A., & Rector, N. A. (2009) · The Canadian Journal of Psychiatry · doi:10.1177/070674370905400707 · Cited by 30
Soomro, G. M. (2012) · Springer eBooks · doi:10.1007/springerreference_223981 · Cited by 33
Skarphéðinsson, G., Compton, S. N., Thomsen, P. H., Weidle, B., Dahl, K., Nissen, J. B., Torp, N. C., Hybel, K. A., Melin, K., Valderhaug, R., et al. (2015) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2014.0167 · Cited by 34
Aripiprazole augmentation in treatment-refractory obsessive–compulsive disorder
Sarkar, R., Klein, J., & Krüger, S. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1091-1 · Cited by 31
“Approximately half of OCD patients treated with an adequate trial of SSRIs fail to fully respond and continue to exhibit significant symptoms (Bloch et al 2006).”
Are 5‐HT3antagonists effective in obsessive–compulsive disorder? A systematic review of literature
Serata, D., Kotzalidis, G. D., Rapinesi, C., Janiri, D., Di Pietro, S., Callovini, G., Piacentino, D., Gasperoni, C., Brugnoli, R., Ferri, V. R., et al. (2015) · Human Psychopharmacology: Clinical and Experimental · doi:10.1002/hup.2461 · Cited by 30
Vitamin D levels in children and adolescents with obsessive compulsive disorder
Yazıcı, K. U., Yazıcı, İ. P., & Üstündağ, B. (2017) · Nordic Journal of Psychiatry · doi:10.1080/08039488.2017.1406985 · Cited by 31
Silver, H., Susser, E., Danovich, L., Bilker, W. B., Youdim, M. B. H., Goldin, V., & Weinreb, O. (2010) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145710001471 · Cited by 30
Metin, S. Z., Ballı, T., Metin, B., Erguzel, T. T., Yiğit, S., Arıkan, M. K., & Tarhan, N. (2019) · Clinical EEG and Neuroscience · doi:10.1177/1550059419879569 · Cited by 29
Management of Clozapine-Induced Obsessive–Compulsive Symptoms in a Man with Schizophrenia
Zink, M., Knopf, U., & Kuwilsky, A. (2007) · Australian & New Zealand Journal of Psychiatry · doi:10.1080/00048670601172806 · Cited by 29
Obsessive–compulsive spectrum disorders: still in search of the concept-affirming boundaries
Starčević, V., & Janča, A. (2010) · Current Opinion in Psychiatry · doi:10.1097/yco.0b013e32833f3b58 · Cited by 33
Simpson, H. B., & Reddy, Y. C. J. (2014) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2013-1229 · Cited by 33
Management of Treatment-Resistant Obsessive-Compulsive Disorder
Gershkovich, M., Wheaton, M. G., & Simpson, H. B. (2017) · Current Treatment Options in Psychiatry · doi:10.1007/s40501-017-0127-8 · Cited by 32
Zheng, H., Jia, F., Han, H., Wang, S., Guo, G., Quan, D., Li, G., & Huang, H. (2019) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2018.12.010 · Cited by 28
The Phenomenology of Obsessive-Compulsive Symptoms in Tourette Syndrome
Ferrão, Y. A., de Alvarenga, P. G., Hounie, A. G., de Mathis, M. A., do Rosário, M. C., & Miguel, E. C. (2013) · Oxford University Press eBooks · doi:10.1093/med/9780199796267.003.0003 · Cited by 29
Suhas, S., Malo, P. K., Kumar, V., Issac, T. G., Chithra, N. K., Bhaskarapillai, B., Reddy, Y. C. J., & Rao, N. P. (2022) · The World Journal of Biological Psychiatry · doi:10.1080/15622975.2022.2082525 · Cited by 33
“It is important to note that the inconsistent and differential efficacy of the atypical antipsychotics for SRI-resistant OCD has been pointed out earlier (Kim et al. 2018).”
BackgroundInfluentialda Rocha, F. F., & Corrêa, H. (2011) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e318223421f · Cited by 28
“Novel treatment interventions must be developed for the roughly two thirds of treatment-refractory OCD patients who do not respond to antipsychotic augmentation, the most studied strategy for these patients.(4)”
BackgroundSuccessful augmentation with aripiprazole in clomipramine-refractory obsessive–compulsive disorder
da Rocha, F. F., & Corrêa, H. (2007) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2007.07.008 · Cited by 28
Olbrich, H., Jahn, I., Stengler, K., Seifritz, E., & Colla, M. (2022) · Clinical Neurophysiology · doi:10.1016/j.clinph.2022.02.029 · Cited by 31
“The specificity and sensitivity for this marker was in the range of a clinically meaningful parameter that could guide decisions for early treatment augmentation, e.g. with antipsychotics in the treatment of OCD (Bloch et al., 2006; Dold et al., 2013).”
BackgroundInfluentialWheaton, M. G., Rosenfield, D., Foa, E. B., & Simpson, H. B. (2015) · Journal of Consulting and Clinical Psychology · doi:10.1037/ccp0000025 · Cited by 24
“About one-third of adults with OCD respond to an antipsychotic (Bloch et al., 2006, Dold et al., 2013; Skapinakis, Papatheodorou, & Mavreas, 2007), but what predicts response is less clear.”
BackgroundElectroacupuncture for Refractory Obsessive-Compulsive Disorder: A Pilot Waitlist-Controlled Trial
Zhang, Z., Wang, X., Tan, Q., Jin, G., & Yao, S.-M. (2009) · The Journal of Nervous and Mental Disease · doi:10.1097/nmd.0b013e3181b05fd1 · Cited by 29
“, 2008) and 32% in antipsychotic augmentation in refractory OCD (Bloch et al., 2006), although no significant difference was observed as compared with the waitlist control group (33.”
ResultInfluentialChertkow, Y., Weinreb, O., Youdim, M. B. H., & Silver, H. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0255-4 · Cited by 30
“(2006) SSRI OCD Bloch et al. (2006), Erzegovesi et al.”
Ivarsson, T., Thomsen, P. H., Dahl, K., Valderhaug, R., Weidle, B., Nissen, J. B., Englyst, I., Christensen, K., Torp, N. C., & Melin, K. (2010) · Child & Youth Care Forum · doi:10.1007/s10566-010-9097-3 · Cited by 29
Hoffman, K. L., & Morales, R. I. R. (2012) · Behavioural Brain Research · doi:10.1016/j.bbr.2012.01.041 · Cited by 31
Pharmacological treatment for obsessive–compulsive disorder
Fineberg, N. A., & Craig, K. J. (2007) · Psychiatry · doi:10.1016/j.mppsy.2007.04.001 · Cited by 26
Quetiapine: novel uses in the treatment of depressive and anxiety disorders
Ravindran, A. V., Al‐Subaie, A., & Abraham, G. (2010) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2010.515586 · Cited by 30
“High-dose quetiapine augmentation was effective in the case of a complex patient with OCD, Tourette’s syndrome (TS) and SRI-induced mania [103].”
BackgroundInfluentialInflammation, Obsessive-Compulsive Disorder, and Related Disorders
Meyer, J. H. (2021) · Current topics in behavioral neurosciences · doi:10.1007/7854_2020_210 · Cited by 29
Effects of mood stabilizers on marble-burying behavior in mice: Involvement of GABAergic system
Egashira, N., Abe, M., Shirakawa, A., Niki, T., Mishima, K., Iwasaki, K., Oishi, R., & Fujiwara, M. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2904-9 · Cited by 29
“There is evidence that treatments combining SSRIs and antipsychotics may alleviate symptoms in schizophrenia, and may also be effective against resistant symptoms in OCD and affective disorder (Bloch et al. 2006).”
BackgroundClinical Pharmacology of Comorbid Obsessive–Compulsive Disorder in Tourette Syndrome
Neri, V., & Cardona, F. (2013) · International review of neurobiology · doi:10.1016/b978-0-12-411546-0.00013-5 · Cited by 25
Do all obsessive-compulsive disorder subtypes respond to medication?
Grados, M. A., & Riddle, M. A. (2008) · International Review of Psychiatry · doi:10.1080/09540260801889153 · Cited by 29
“This benefit, however, may only apply to 1/3 of the SSRI-resistant patients among whom the tic-related subtype may be overrepresented (Bloch et al., 2006).”
BackgroundThe South African Society of Psychiatrists (SASOP) Treatment Guidlelines for Psychiatric Disorders
Emsley, R. A., Flisher, A. J., Grobler, G. P., Seedat, S., & Szabo, C. P. (2013) · South African Journal of Psychiatry · doi:10.4102/sajpsychiatry.v19i3.942 · Cited by 28
The Pharmacological Treatment of Obsessive-Compulsive Disorder
Pittenger, C. (2023) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2022.11.005 · Cited by 28
van Balkom, A. J. L. M., Emmelkamp, P. M. G., Eikelenboom, M., Hoogendoorn, A. W., Smit, J. H., & van Oppen, P. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000339369 · Cited by 24
Drummond, L. M., Fineberg, N. A., Heyman, I., Kolb, P. J., Pillay, A., Rani, S., Salkovskis, P. M., & Veale, D. M. (2008) · Psychiatric Bulletin · doi:10.1192/pb.bp.107.017517 · Cited by 24
Shafti, S. S., & Kaviani, H. (2014) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125314560739 · Cited by 29
Wexler, B. E., Vitulano, L. A., Moore, C. C., Katsovich, L., Smith, S. D., Rush, C., Grantz, H., Dong, J., & Leckman, J. F. (2020) · Psychological Medicine · doi:10.1017/s0033291720000288 · Cited by 29
“Thirty percent is also consistent with criteria used in studies to define the treatment response in other disorders (e.g. Bloch et al., 2006; Pallanti, Querciol, Sood, & Hollander, 2002; Storch, Lewin, De Nadai, & Murphy, 2010; Suzuki et al., 2012).”
ResultSelf-citationNew Pharmacotherapeutic Approaches to Obsessive-Compulsive Disorder
Figee, M., & Denys, D. A. J. P. (2009) · CNS Spectrums · doi:10.1017/s1092852900027255 · Cited by 26
Are Mentalizing Abilities and Insight Related to the Severity of Obsessive-Compulsive Disorder
İnanç, L., & Altıntaş, M. (2018) · Psychiatry Investigation · doi:10.30773/pi.2018.05.02.2 · Cited by 24
[Resistance and refractoriness in obsessive-compulsive disorder].
Ferrão, Y., Diniz, J., Lopes, A., Shavitt, R., Greenberg, B., & Miguel, E. (2007) · Revista Brasileira de Psiquiatria · doi:10.1590/s1516-44462006005000059 · Cited by 23
Pharmacologic treatment of obsessive-compulsive disorder comorbidity
Pallanti, S., & Grassi, G. (2014) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2014.964208 · Cited by 25
Error-Related Negativity and Tic History in Pediatric Obsessive-Compulsive Disorder
Hanna, G. L., Carrasco, M., Harbin, S. M., Nienhuis, J. K., LaRosa, C. E., Chen, P., Fitzgerald, K. D., & Gehring, W. J. (2012) · F1000Research · doi:10.7490/f1000research.1090231.1 · Cited by 23
Park, H. R., Kim, I. H., Kang, H., McCairn, K. W., Lee, D. S., Kim, B.-N., Kim, D. G., & Paek, S. H. (2019) · PLoS ONE · doi:10.1371/journal.pone.0219578 · Cited by 28
Tucci, M. C., Dvorkin‐Gheva, A., Sharma, R., Taji, L., Cheon, P., Peel, J. K., Kirk, A., & Szechtman, H. (2014) · Psychopharmacology · doi:10.1007/s00213-014-3505-6 · Cited by 24
“The success of this pharmacotherapy is often enhanced through coadministration of various dopamine blockers (Bloch et al. 2006; Denys 2006; Dougherty et al. 2004; Fineberg et al. 2006), raising the current hypothesis of a dopamine-serotonin interaction in OCD (Goodman et al.”
BackgroundA study of poor insight in social anxiety disorder
Vigne, P., de Menezes, G. B., Harrison, B. J., & Fontenelle, L. F. (2014) · Psychiatry Research · doi:10.1016/j.psychres.2014.05.033 · Cited by 23
“Although there is evidence that antipsychotic augmentation therapy is beneficial in SRI-resistant OCD cases (Bloch et al., 2006), this strategy has been linked with potentially severe side effects (Meyer, 2007) and may not be effective when employed as a monotherapy in OCD-related disorders (Keuneman et al.”
BackgroundEmerging drugs to treat obsessive–compulsive disorder
Pallanti, S., Grassi, G., & Cantisani, A. (2013) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2014.875157 · Cited by 26
“However, only a third of resistant patients respond to this treatment [55].”
BackgroundPittenger, C., Brennan, B. P., Koran, L. M., Mathews, C. A., Nestadt, G., Pato, M. T., Phillips, K. A., Rodríguez, C. I., Simpson, H. B., Skapinakis, P., et al. (2021) · Psychiatry Research · doi:10.1016/j.psychres.2021.113853 · Cited by 24
McLean, C. P., Zandberg, L. J., Meter, P. E. V., Carpenter, J. K., Simpson, H. B., & Foa, E. B. (2015) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.14m09513 · Cited by 25
Sahraian, A., Ehsaei, Z., & Mowla, A. (2018) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2018.03.014 · Cited by 26
“In previous studies, aripiprazole showed to have curative effects for OC symptoms in inpatients or outpatients suffering from OCD with good tolerability and safety (Akyol Ardic et al., 2017; Masi et al., 2010; Dold et al., 2015; Bloch et al., 2016; Pessina et al., 2009).”
BackgroundAnxiety Symptoms Differ in Youth With and Without Tic Disorders
Vermilion, J. A., Pedraza, C., Augustine, E. F., Adams, H., Vierhile, A., Lewin, A. B., Collins, A. T., McDermott, M., O’Connor, T., Kurlan, R., et al. (2020) · Child Psychiatry & Human Development · doi:10.1007/s10578-020-01012-6 · Cited by 23
Aripiprazole as an Augmentation Agent in Treatment-Resistant Body Dysmorphic Disorder
Uzun, Ö., & Özdemir, B. H. (2010) · Clinical Drug Investigation · doi:10.2165/11536730-000000000-00000 · Cited by 21
COMT Val158Met Polymorphism and Executive Functions in Obsessive-Compulsive Disorder
Tükel, R., Gurvit, H. I., Öztürk, N., Özata, B., Ertekin, B. A., Ertekin, E., Baran, B., Kalem, Ş. A., Büyükgök, D., & Direskeneli, G. S. (2013) · Journal of Neuropsychiatry · doi:10.1176/appi.neuropsych.12040103 · Cited by 23
Weber, S. R., Wehr, A. M., & Duchemin, A. (2015) · Journal of Affective Disorders · doi:10.1016/j.jad.2015.11.031 · Cited by 22
“One review (Bloch et al., 2006) of nine studies involving 278 participants supported use of haloperidol and risperidone for treatmentrefractory OCD with about one-third of refractory OCD patients responding to the added antipsychotic, whereas data were inconclusive regarding quetiapine and olanzapine.”
BackgroundBurk, B. G., DiGiacomo, T., Polancich, S., Pruett, B. S., Sivaraman, S., & Birur, B. (2023) · Acta Psychiatrica Scandinavica · doi:10.1111/acps.13567 · Cited by 27
“7), but nearly one-third of patients still exhibited refractory symptoms.(46) While aripiprazole was not included in this analysis, risperidone and haloperidol appeared efficacious, but olanzapine and quetiapine did not.”
BackgroundPharmacoepidemiology of obsessive–compulsive disorder: A Swedish nationwide cohort study
Isomura, K., Nordsletten, A. E., Rück, C., Ljung, R., Ivarsson, T., Larsson, H., & Mataix‐Cols, D. (2016) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2016.02.004 · Cited by 20
Pharmacotherapy of obsessive-compulsive disorder during pregnancy: a clinical approach
Uğuz, F. (2015) · Brazilian Journal of Psychiatry · doi:10.1590/1516-4446-2015-1673 · Cited by 20
Treatment Resistance in Obsessive-Compulsive Disorder
Middleton, R., Wheaton, M. G., Kayser, R., & Simpson, H. B. (2019) · Treatment Resistance in Psychiatry · doi:10.1007/978-981-10-4358-1_11 · Cited by 19
Psychedelics, OCD and related disorders: A systematic review
Graziosi, M., Rohde, J. S., Tiwari, P., Siev, J., & Yaden, D. B. (2024) · Journal of Obsessive-Compulsive and Related Disorders · doi:10.1016/j.jocrd.2024.100873 · Cited by 23
Neuropsychiatric effects of subthalamic deep brain stimulation
Mosley, P. E., & Akram, H. (2021) · Handbook of clinical neurology · doi:10.1016/b978-0-12-820107-7.00026-4 · Cited by 22
Pharmacological Treatment of Internet Addiction
Camardese, G., Leone, B., Walstra, C., Janiri, L., & Guglielmo, R. (2015) · Studies in neuroscience, psychology and behavioral economics · doi:10.1007/978-3-319-07242-5_10 · Cited by 27
“Prescription of atypical antipsychotics seems to be a highly helpful strategy for treatment-resistant obsessive-compulsive disorder, with benefits most evident for risperidone (Bloch et al. 2006).”
BackgroundObsessive-Compulsive Disorder: Diagnosis, Epidemiology, Etiology, and Treatment
Sassano-Higgins, S. A., & Pato, M. T. (2015) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.130211 · Cited by 29
Tic-related obsessive–compulsive disorder
Pringsheim, T. M., & Piacentini, J. C. (2018) · Journal of Psychiatry and Neuroscience · doi:10.1503/jpn.180086 · Cited by 18
Girone, N., Benatti, B., Bucca, C., Cassina, N., Vismara, M. E. M., & Dell’Osso, B. M. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.02.009 · Cited by 19
Umehara, H., Numata, S., Tajima, A., Nishi, A., Nakataki, M., Imoto, I., Sumitani, S., & Ohmori, T. (2016) · PLoS ONE · doi:10.1371/journal.pone.0157232 · Cited by 18
“However, how to use antipsychotic drugs, such as the choice, optimal dose, and duration, has not been still established [3,4,5,6].”
BackgroundZhang, C., Chen, Y., Tian, S., Wang, T., Xie, Y., Jin, H., Lin, G., Gong, H., Zeljic, K., Sun, B., et al. (2017) · Frontiers in Psychology · doi:10.3389/fpsyg.2017.01814 · Cited by 18
Vahabzadeh, A. B. N., & McDougle, C. J. (2014) · Elsevier eBooks · doi:10.1016/b978-0-12-386456-7.05213-8 · Cited by 19
Poppe, C., Müller, S. T., Greil, W., Walder, A., Grohmann, R., & Stübner, S. (2016) · Journal of Affective Disorders · doi:10.1016/j.jad.2016.04.035 · Cited by 19
Clinical Course and Adult Outcome in Tourette Syndrome
Bloch, M. H. (2013) · Oxford University Press eBooks · doi:10.1093/med/9780199796267.003.0005 · Cited by 20
Self-citationVellucci, L., Ciccarelli, M., Buonaguro, E. F., Fornaro, M., D’Urso, G., Simone, G. D., Iasevoli, F., Barone, A., & de Bartolomeis, A. (2023) · Biomolecules · doi:10.3390/biom13081220 · Cited by 20
Neurofeedback for obsessive compulsive disorder: A randomized, double-blind trial
Rance, M., Zhao, Z., Zaboski, B. A., Kichuk, S. A., Romaker, E. K., Koller, W. N., Walsh, C. J., Harris‐Starling, C., Wasylink, S., Adams, T. G., et al. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115458 · Cited by 17
Ramakrishnan, D. S., Farhat, L. C., Vattimo, E. F. D. Q., Levine, J. L. S., Johnson, J. A., Artukoglu, B. B., Landeros‐Weisenberger, A., Zangen, A., Pélissolo, A., Pereira, C. A. D. B., et al. (2024) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2024.03.044 · Cited by 17
Self-citationTreating refractory obsessive-compulsive disorder: what to do when conventional treatment fails?
Franz, A. P., Paim, M. F., de Araújo, R. M. F., Rosa, V. D. O., Barbosa, Í. M., Blaya, C., & Ferrão, Y. A. (2013) · Trends in Psychiatry and Psychotherapy · doi:10.1590/s2237-60892013000100004 · Cited by 17
Albert, U., Barbaro, F., Aguglia, A., Maina, G., & Bogetto, F. (2012) · Rivista di psichiatria · doi:10.1708/1139.12553 · Cited by 20
Albert, U., Salvo, G. D., Solia, F., Rosso, G., & Maina, G. (2019) · Current Medicinal Chemistry · doi:10.2174/0929867324666170712114445 · Cited by 16
Najera, R. A., Gregory, S. T., Shofty, B., Anand, A., Gadot, R., Youngerman, B. E., Storch, E. A., Goodman, W. K., & Sheth, S. A. (2022) · Journal of neurosurgery · doi:10.3171/2022.5.jns22474 · Cited by 16
Albert, U., Aguglia, A., Bogetto, F., Cieri, L., Daniele, M., Maina, G., Necci, R., Parena, A., Salvati, L., & Tundo, A. (2012) · Psychotherapy and Psychosomatics · doi:10.1159/000336873 · Cited by 19
Tucci, M. C., Dvorkin‐Gheva, A., Johnson, E., Cheon, P., Taji, L., Agarwal, A., Foster, J. A., & Szechtman, H. (2014) · European Journal of Neuroscience · doi:10.1111/ejn.12652 · Cited by 16
“By the same token, the present findings strongly support the current clinical attempts of targeting simultaneously DA and 5-HT activity as a viable pharmacotherapeutic strategy for OCD (Greist et al., 2003; Dougherty et al., 2004; Koran, 2004; Marazziti et al., 2004; Bloch et al., 2006).”
Miodownik, C., Bergman, J., Lerner, P. P., Kreinin, A., & Lerner, V. (2015) · Clinical Neuropharmacology · doi:10.1097/wnf.0000000000000065 · Cited by 19
“efficacy of quetiapine and olanzapine was inconclusive.(40) In most studies, response occurred within 1 month of augmentation.”
BackgroundWen, S., Cheng, M., Cheng, M., Yue, J., & Wang, H. (2013) · Behavioral and Brain Functions · doi:10.1186/1744-9081-9-31 · Cited by 19
“Only one third of treatment-refractory OCD patients show a meaningful treatment response to antipsychotic augmentation [13].”
BackgroundAdvances in the management of treatment-resistant anxiety disorders
Lanouette, N. M., & Stein, M. B. (2010) · Focus · doi:10.1176/foc.8.4.foc501 · Cited by 15
Talaeı, A., Hosseini, F. F., Aghili, Z., Akhondzadeh, S., Asadpour, E., Mehramiz, N. J., & Forouzanfar, F. (2020) · Canadian Journal of Physiology and Pharmacology · doi:10.1139/cjpp-2019-0381 · Cited by 17
de Brouwer, G., Fick, A., Lombaard, A., Stein, D. J., Harvey, B. H., & Wolmarans, D. W. (2020) · Behavioural Brain Research · doi:10.1016/j.bbr.2020.112794 · Cited by 16
Evidenzbasierte Pharmakotherapie und andere somatische Therapieverfahren bei Zwangsstörungen
Kordon, A., Zurowski, B., Wahl, K., & Hohagen, F. (2011) · Der Nervenarzt · doi:10.1007/s00115-010-2963-2 · Cited by 21
Psychotherapy and medication management strategies for obsessive-compulsive disorder
Walsh, K. H., & McDougle (2011) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s13205 · Cited by 17
“Quetiapine is the most studied neuroleptic in OCDs, with four controlled studies, only one of which demonstrated clinical significance.(100,105) Response to neuroleptic augmentation is much quicker than response to a SRI alone; most patients demonstrate response within 4 weeks.”
Management of tics and Tourette's disorder: an update
Bestha, D. P., Jeevarakshagan, S., & Madaan, V. (2010) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2010.486402 · Cited by 17
Dell’Osso, B. M., Vismara, M. E. M., Benatti, B., Cirnigliaro, G., Grancini, B. M., Fineberg, N. A., Ameringen, M. V., Hollander, E., Stein, D. J., Menchón, J. M., et al. (2019) · CNS Spectrums · doi:10.1017/s1092852919001068 · Cited by 17
Storch, E. A., McKay, D., Reid, J. M., GELLER, D. A., Goodman, W. K., Lewin, A. B., & Murphy, T. K. (2010) · Child & Youth Care Forum · doi:10.1007/s10566-010-9094-6 · Cited by 15
“Although the latter has support in adults with OCD (Bloch et al. 2006), there is limited data available on the use of atypical antipsychotic augmentation in youth with OCD.”
BackgroundObsessive-Compulsive Disorder:An Open-Label Pilot Trial of Escitalopram
Almeida, A. G.-D., Quarantini, L. C., Góis, C. R., Santos‐Jesus, R., Miranda‐Scippa, Â., de Oliveira, I. R., Prado, H. D. S., Leckman, J. F., & do Rosário, M. C. (2007) · CNS Spectrums · doi:10.1017/s1092852900021258 · Cited by 15
“Therefore, the investigation of new treatment approaches is extremely relevant to improve the quality of life of these patients.(14) Escitalopram is the S-enantiomer of citalopram and the most selective of the SSRIs.”
BackgroundSelf-citationYin, L., Han, F., & Wang, Q. (2023) · Cognitive Neurodynamics · doi:10.1007/s11571-023-09999-z · Cited by 16
“For some medication-naive OCD patients, dopaminergic drugs work well as a complementary treat-ment, such as Risperidone (McDougle et al. 1994; Bloch et al. 2006).”
Martiadis, V., Pessina, E., Martini, A., Raffone, F., Cattaneo, C. I., Berardis, D. D., & Pampaloni, I. (2024) · CNS Spectrums · doi:10.1017/s1092852924000348 · Cited by 19
“…been examined, although the results are inconsistent and multiple meta-analyses have been unable to demonstrate their superiority versus placebo 5,9 – 11 ; paliperidone has been studied in treatment-resistant OCD patients in one randomized, placebo-controlled trial of 8 weeks showing significant…”
Aripiprazole augmentation in poor insight obsessive-compulsive disorder: a case report
Fornaro, M., Gabrielli, F., Mattei, C., Vinciguerra, V., & Fornaro, P. (2008) · Annals of General Psychiatry · doi:10.1186/1744-859x-7-26 · Cited by 14
High-Dose Duloxetine for Treatment-Resistant Obsessive-Compulsive Disorder
Yeh, Y., Chen, C., Kuo, S.-C., Wang, S.-C., Chen, C.-K., & Feng, H.-M. (2009) · Clinical Neuropharmacology · doi:10.1097/wnf.0b013e31817f8cef · Cited by 14
Hantouche, E. G., & Demonfaucon, C. (2008) · L Encéphale · doi:10.1016/j.encep.2007.12.008 · Cited by 17
Frías, Á., Palma, C., & Farriols, N. (2014) · Actas Españolas de Psiquiatría · Cited by 24
Hasanpour, H., Meibodi, R. G., Navi, K., & Asadi, S. (2018) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s173388 · Cited by 15
Lai, C. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990393 · Cited by 15
Metadata
- Authors
- Bloch, M. H., Landeros-Weisenberger, A., Kelmendi, B., Coric, V, Bracken, M. B., & Leckman, J. F.
- Affiliations
- Yale University (US)
- Connecticut Mental Health Center (US)
- Corresponding author
- Bloch, M H
- Venue
- Molecular Psychiatry
- Published
- 2006-04-04
- Volume
- 11
- Issue
- 7
- Pages
- 622-632
- ISSN
- 1359-4184 (ISSN-L)
- 1476-5578
- OpenAlex
- W2100202859
- Cited by
- 635
- References
- 50
- Citations by year
- 2026: 24 · 2025: 21 · 2024: 22 · 2023: 14 · 2022: 18 · 2021: 25 · 2020: 21 · 2019: 29 · 2018: 34 · 2017: 37 · 2016: 30 · 2015: 53 · 2014: 48 · 2013: 39 · 2012: 39
- FWCI
- 5.03
- Type
- journal article
- Language
- en
- Update notices
- erratum (2006-07-26)
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Molecular Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Tourette Association of America
- National Institutes of Health
- U.S. Public Health Service
- National Institute of Mental Health
- Topics
- Social Sciences › Psychology › Clinical Psychology › Obsessive-Compulsive Spectrum Disorders
- Social Sciences › Psychology › Clinical Psychology › Psychoanalysis and Psychopathology Research
- Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
- Keywords
- obsessive-compulsive disorder, treatment-refractory OCD, antipsychotic augmentation, serotonin reuptake inhibitors, haloperidol, risperidone, quetiapine, olanzapine, treatment response, Yale-Brown Obsessive Compulsive Scale
- MeSH terms
- Quetiapine Fumarate, Olanzapine, Adult, Aged, Basal Ganglia Diseases, Benzodiazepines, Depressive Disorder, Dibenzothiazepines, Double-Blind Method, Drug Resistance, Drug Therapy, Combination, Haloperidol, Humans, Middle Aged, Obsessive-Compulsive Disorder, Patient Dropouts, Tic Disorders, Antipsychotic Agents, Comorbidity, Randomized Controlled Trials as Topic, Treatment Outcome, Selective Serotonin Reuptake Inhibitors, Risperidone
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.